Sumitovant Biopharma Ltd. didn’t just hit the ground running when it launched as a subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (DSP) at the end of 2019, and as the parent company for five companies acquired for $3bn from Roivant Sciences Inc. – it never broke its stride, since the portfolio was seamlessly integrated into DSP after the deal closed, according to Sumitovant CEO Myrtle Potter.
Potter noted that “oftentimes, two organizations come together … and it takes companies two or three years to go through the integration process, decide who gets the top job, who's being eliminated, what the layoffs look like, etc. That didn't happen in this situation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?